Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung

Q4 Medicine Forum of Clinical Oncology Pub Date : 2015-06-01 DOI:10.1515/fco-2015-0009
H. Shafik, M. Ashour
{"title":"Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung","authors":"H. Shafik, M. Ashour","doi":"10.1515/fco-2015-0009","DOIUrl":null,"url":null,"abstract":"Abstract Introduction: Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. The frequency of epidermal growth factor receptor (EGFR) mutations is ethnicity-dependent, with a higher proportion in Asian populations than in whites, while the incidence of EML4-ALK (echinoderm microtubule-associated-protein like 4-anaplastic lymphoma kinase) fusion gene ranged from 1.6% to 16.4% in patients with NSCLC and these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. This study was conducted to determine the frequency of EGFR mutation and EML4-ALK fusion gene in our population and to determine the effect of different clinicopathological features on the expression of those mutations in patients with lung adenocarcinoma. Results: EGFR mutations were detected in approximately 33% of our patients in this series; the most frequently detected mutation was exon 19 deletion. EML4-ALK fusion gene was detected in 7.3% of patients. Conclusion: Our population exhibited the incidence of EGFR mutation approximately similar to that reported in East Asia and Japanese patients, higher than that recorded in USA, and Australia. However, more studies with larger patients’ numbers are needed to verify this finding.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"6 1","pages":"19 - 23"},"PeriodicalIF":0.0000,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/fco-2015-0009","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/fco-2015-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Abstract Introduction: Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. The frequency of epidermal growth factor receptor (EGFR) mutations is ethnicity-dependent, with a higher proportion in Asian populations than in whites, while the incidence of EML4-ALK (echinoderm microtubule-associated-protein like 4-anaplastic lymphoma kinase) fusion gene ranged from 1.6% to 16.4% in patients with NSCLC and these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. This study was conducted to determine the frequency of EGFR mutation and EML4-ALK fusion gene in our population and to determine the effect of different clinicopathological features on the expression of those mutations in patients with lung adenocarcinoma. Results: EGFR mutations were detected in approximately 33% of our patients in this series; the most frequently detected mutation was exon 19 deletion. EML4-ALK fusion gene was detected in 7.3% of patients. Conclusion: Our population exhibited the incidence of EGFR mutation approximately similar to that reported in East Asia and Japanese patients, higher than that recorded in USA, and Australia. However, more studies with larger patients’ numbers are needed to verify this finding.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿拉伯肺腺癌患者EGFR突变频率及EML4-ALK融合基因
摘要:通过鉴定其发病机制的分子事件,可能会改善肺癌的临床预后。表皮生长因子受体(EGFR)突变的频率是种族依赖性的,亚洲人群的比例高于白人,而EML4-ALK(棘皮微管相关蛋白样4-间变性淋巴瘤激酶)融合基因在非小细胞肺癌患者中的发病率从1.6%到16.4%不等,这些个体与表皮生长因子受体基因突变的个体不同。本研究旨在确定我们人群中EGFR突变和EML4-ALK融合基因的频率,并确定不同的临床病理特征对肺腺癌患者中这些突变表达的影响。结果:在该系列研究中,约33%的患者检测到EGFR突变;最常检测到的突变是外显子19的缺失。7.3%的患者检测到EML4-ALK融合基因。结论:我们的人群EGFR突变的发生率与东亚和日本患者的报道大致相似,高于美国和澳大利亚的记录。然而,需要更多的患者数量的研究来验证这一发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Forum of Clinical Oncology
Forum of Clinical Oncology Medicine-Oncology
CiteScore
0.50
自引率
0.00%
发文量
3
审稿时长
6 weeks
期刊最新文献
Breast cancer recurrence and tumor size: A bibliometric analysis Outcomes of patients with localized prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy boost: A single-center retrospective study Glomerulonephritis as a paraneoplastic event from prostate cancer relapse Change of dosing paradigm in oncology Total neoadjuvant therapy in rectal cancer: a review across studies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1